Independent US psoriasis registry to track drug safety
Click Here to Manage Email Alerts
The first independent U.S. psoriasis registry will begin recruiting patients later this year, according to the National Psoriasis Foundation and Corrona.
The registry is a joint collaboration between the two organizations and will initially track drug safety reporting for Cosentyx (secukinumab, Novartis Pharmaceuticals), a recently FDA-approved biologic treatment for moderate-to-severe psoriasis, according to a press release. The Corrona Psoriasis Registry is expected to enroll at least 3,000 patients with psoriasis being treated with secukinumab, with follow-up for at least 8 years. Novatis is the first subscriber to the registry, the release stated.
The registry is currently recruiting investigators in the registry. Patients will be recruited in the second quarter of 2015, according to a Corrona representative.
Comprehensive questionnaires completed by patients and dermatologists during appointments will be used to gather data for the registry.
“This registry will help determine which treatments are safest and most effective for psoriasis in the long-term,” Bruce Strober, MD, scientific director for the registry, said in the release.
Possible causes for psoriasis, the relationship between psoriasis and other health conditions and the impact of the disease on the quality of life also will be addressed through the registry, according to the release.
Reference: www.psoriasis.org.